Table 3.
Impacts of clinicopathologic features on relapse in 58 APL patients during maintenance therapy
| Clinicopathologic parameters | Outcome
|
P-value | |
|---|---|---|---|
| Remission | Relapse | ||
| Sex | 0.432 | ||
| Male | 26 | 5 | |
| Female | 25 | 2 | |
| Age (years) | 1.000 | ||
| ≤40 | 25 | 3 | |
| >40 | 26 | 4 | |
| WBC count (×109/L) | 0.592 | ||
| ≤5 | 43 | 5 | |
| >5 | 8 | 2 | |
| Platelet count (×109/L) | 0.661 | ||
| ≤40 | 35 | 6 | |
| >40 | 16 | 1 | |
| Hemoglobin (g/L) | 0.083 | ||
| <100 | 39 | 3 | |
| ≥100 | 12 | 4 | |
| Induction regimens | 0.327 | ||
| ATRA+As2O3+IDA | 11 | 0 | |
| ATRA+IDA | 40 | 7 | |
| Maintenance regimens | 0.004 | ||
| ATRA+As2O3 | 30 | 0 | |
| ATRA+chemotherapy | 21 | 7 | |
Abbreviations: APL, acute promyelocytic leukemia; As2O3, arsenic trioxide; ATRA, all-trans retinoic acid; IDA, idarubicin; WBC, white blood cell.